AnalystBook Research · Company Intelligence

CHIMERA INVESTMENT CORP

CIMNYSE

Built from CHIMERA INVESTMENT CORP's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Chimera earned more, but cash flow swung negative.

The read at a glance✓ Audited against SEC data
  • Business mixMortgage assets and lendingNote
  • Net income$230.5M, +30.9%OK
  • Operating cash flow($248.9M), weakerWatch
  • Dividends$122.7M, +3.0%Note
  • Debt$251.5M, +86.8%Watch
  • InsidersNo purchases or salesNote

Business

Chimera is a mortgage-focused business that invests in residential mortgage loans, RMBS, Agency and Non-Agency mortgage assets, MSRs, and related real estate assets.

Where the revenue comes from

Fiscal 2025, as CHIMERA INVESTMENT CORP reports it. History and quarterly detail are in the app.

  • Investment Management And Advisory$263.1M
  • Mortgage Origination$3.3M

Leadership changes

From CHIMERA INVESTMENT CORP's own filings, the day they're filed.

  • Dan Thakkar · departureeff. 2025-07-01
  • Susan Mills · Director · appointmenteff. 2023-11-13
  • Indiana Bond Bank · departure

Latest filings

  • 8-K · Company announcement2026-08-05
  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-05
  • 8-K · Company announcement2026-06-11
  • 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about CHIMERA INVESTMENT CORP, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.